BioSpace News Archive

—CanSeq150 Initiative will use 10x Genomics’ Chromium de novo Assembly Solution to generate high quality, cost-effective assemblies for new genomes—

QurAlis Corporation, a new private biotech company focused on developing precision solutions to cure ALS, today announced the addition of biotech investors MP Healthcare Venture Management (MPH), Amgen Ventures, and Alexandria Venture Investments, who have joined the fight to cure Amyotrophic Lateral Sclerosis (ALS).

Rebiotix’s RBX2660 is a non-antibiotic treatment in Phase 3 development for the prevention of recurrent Clostridium difficile infection (CDI) and has the potential to be the world’s first approved human microbiome product

DalCor today announced that the company will increase enrollment in its ongoing Phase 3 clinical trial of dalcetrapib from 5000 to 6000 patients.

Expanded Menu to Provide Tests for Drugs of Abuse Such as Opiates and Drugs for Other Chronic Conditions

MGTA-456 is a first-in-class allogeneic stem cell therapy consisting of a single umbilical cord blood unit expanded with an aryl hydrocarbon receptor (AHR) antagonist then administered to a patient through a bone marrow transplant.

Trial examines use of synthetic endocannabinoid mimetic with no psychotropic properties to treat lupus inflammation

SiteOne Therapeutics, a private biopharmaceutical company advancing novel non-opioid pain therapeutics, today announces the addition of some of the world’s leading medical and scientific experts in the treatment of acute and chronic pain to its Scientific Advisory Board.

Neosante Health Solutions’ top-selling Delictase® Oral Drops will soon be available to a much larger audience on Amazon.com, the world’s largest online retailer.

Acquisition to strengthen UCB’s genomics and epigenomics research platform to identify novel drug targets